First New Oral Antibiotic for C. difficile in 25 Years
Optimer Pharmaceuticals Buoyed by Unanimous Vote
WASHINGTON – Optimism, and eight years of hard work, paid off for Optimer Pharmaceuticals Inc. Tuesday when an FDA advisory committee unanimously recommended approval of Dificid (fidaxomicin) as a treatment for Clostridium difficile infection (CDI).